A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A method of treating or preventing exacerbations of one or more pulmonary hypertension symptoms in a subject in need thereof includes administering to the subject a supplemental medicament for treating, attenuating, and/or preventing one or more pulmonary hypertension symptoms. The subject is concurrently undergoing treatment with one or more primary medicaments for treating pulmonary hypertension. The supplemental medicament may include a dose of treprostinil comprising greater than 10 micrograms of treprostinil. The treprostinil of the supplemental medicament may be administered as a dry powder.
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A combination therapy for treating pulmonary hypertension (e.g., PAH, PH-ILD) includes a dose of treprostinil comprising greater than 10 micrograms of treprostinil and a dose of an ActRIIA fusion protein. The dose of treprostinil and the dose of ActRIIA fusion protein may be administered concurrently or sequentially. Further methods for treating pulmonary hypertension include administering a therapeutically effective amount of ActRIIA fusion protein to a subject who has received a composition containing treprostinil, or administering a composition containing treprostinil to a subject who has received a therapeutically effective amount of ActRIIA fusion protein. The treprostinil may be administered as a dry7 powder or liposomal composition.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
5.
Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Pharmaceuticals and natural remedy preparations for the treatment of respiratory diseases and for systemic delivery via inhalation; Medicinal preparations and substances for the treatment of respiratory diseases and for systemic delivery via inhalation; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension and interstitial lung disease, and idiopathic pulmonary fibrosis; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of pulmonary hypertension; Pharmaceuticals for treatment of respiratory diseases, namely, capsules comprised of microparticles and nanoparticles, comprised of polymers, excipients, therapeutics, and biologics sold as a kit with inhaler Inhalers for medical use, sold empty; Nebulizers for medical purposes; Instruments and apparatus provided empty used for the inhalation of pharmaceuticals; Medical apparatus for facilitating the inhalation of pharmaceutical preparations
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals for treatment of respiratory diseases, namely, pharmaceuticals in the form of capsules comprised of microparticles and nanoparticles composed of polymers, excipients, therapeutics, and biologics; Pharmaceuticals for treatment of respiratory diseases, namely, pharmaceuticals in the nature of microparticles and nanoparticles with prophylactic properties composed of polymers, excipients, therapeutics, and biologics;
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
Produits et services
Biological preparations in the nature of microparticles and nanoparticles comprised of polymers and excipients, used for the manufacture of medical and pharmaceutical goods and for general scientific and research purposes; Custom manufacture of microparticles and nanoparticles, namely, those composed of polymers, excipients, therapeutics, and biologics, for general scientific and research purposes; Custom manufacture of microparticles and nanoparticles, namely, those composed of polymers, excipients, therapeutics, and biologics used for the manufacture of medical and pharmaceutical goods and for general scientific and research purposes; custom manufacture of microparticles and nanoparticles, namely, those composed of polymers, excipients, therapeutics, and biologics used for medical diagnostic and treatment purposes;
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of pulmonary hypertension
10.
Dry powder treprostinil for the treatment of pulmonary hypertension
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
36 - Services financiers, assurances et affaires immobilières
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Business administration of patient support programs and medication financial assistance programs; business administration of drug voucher programs; provision of consumer information in the field of patient financial assistance and support; providing patient support programs, namely, business administration of a program for enabling participants to obtain reduced payment of pharmaceuticals; providing patient assistance programs, namely, business administration of copay assistance programs and prescription voucher programs; Providing information about medication insurance coverage, financial
patient support enrollment, and patient financial assistance; providing
financial support to eligible patients for the purpose of assistance
with pharmaceutical expenses; providing information about
healthcare insurance plans and patient financial assistance;
providing information about the financial administration of patient
support programs; providing patient support programs, namely,
financial coordination with patients for reduced payment of
pharmaceuticals; providing patient assistance programs in the nature
of assisting eligible participants with payment of pharmaceutical
products; financial administration of medication assistance programs
in the nature of providing financial assistance for patients; providing
financial information with respect to pharmaceutical payment; Charitable patient assistance program support services, namely, a patient assistance program to provide prescription pharmaceuticals at reduced or no cost for eligible low-income patients and providing medical information about access to medication; patient assistance support services, namely, providing medical assistance information about medication; patient assistance program to provide drugs free of charge to low-income patients without prescription drug coverage; patient assistance program to provide drugs free of charge to low-income patients with prescription drug coverage; providing medical information about medical assistance patient support programs, medications, and prescriptions;
36 - Services financiers, assurances et affaires immobilières
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Business administration of patient support programs and medication financial assistance programs; business administration of drug voucher programs; provision of consumer information in the field of patient financial assistance and support; providing patient support programs, namely, business administration of a program for enabling participants to obtain reduced payment of pharmaceuticals; providing patient assistance programs, namely, business administration of copay assistance programs and prescription voucher programs; Providing information about medication insurance coverage, financial patient support enrollment, and patient financial assistance; providing financial support to eligible patients for the purpose of assistance with pharmaceutical expenses; providing information about healthcare insurance plans and patient financial assistance; providing information about the financial administration of patient support programs; providing patient support programs, namely, financial coordination with patients for reduced payment of pharmaceuticals; providing patient assistance programs in the nature of assisting eligible participants with payment of pharmaceutical products; financial administration of medication assistance programs in the nature of providing financial assistance for patients; providing financial information with respect to pharmaceutical payment; Charitable patient assistance program support services, namely, a patient assistance program to provide prescription pharmaceuticals at reduced or no cost for eligible low-income patients and providing medical information about access to medication; patient assistance support services, namely, providing medical assistance information about medication; patient assistance program to provide drugs free of charge to low-income patients without prescription drug coverage; patient assistance program to provide drugs free of charge to low-income patients with prescription drug coverage; providing medical information about medical assistance patient support programs, medications, and prescriptions;
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of pulmonary hypertension
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical products development; Development of pharmaceutical and biological preparations and medicines; Research and development in the pharmaceutical and biotechnology fields
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical products development; Development of pharmaceutical and biological preparations and medicines; Research and development in the pharmaceutical and biotechnology fields
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
19.
Dry powder treprostinil for the treatment of pulmonary hypertension
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
20.
Dry powder treprostinil for the treatment of pulmonary hypertension
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
21.
Dry powder treprostinil for the treatment of pulmonary hypertension
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of pulmonary hypertension.
23.
Dry powder treprostinil for the treatment of pulmonary hypertension
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of pulmonary hypertension
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of pulmonary hypertension
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the treatment of pulmonary hypertension
27.
DRY POWDER TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
A61K 9/72 - Préparations médicinales caractérisées par un aspect particulier à fumer ou inhaler
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A composition to induce analgesia includes a plurality of particles, each particle of the plurality having 40-60 wt% amino amide anesthetic or a pharmaceutically acceptable salt, hydrate, or solvate thereof and 60-40 wt% PLGA polymer including 48:52 to 52:48 molar ratio D,L lactide:glycolide and an inherent viscosity of about 0.16 to 0.24 dL/g at 0.1%w/v in chloroform at 25°C. Each particle includes a non-spherical shape less than 100 μιτι in a broadest dimension, and having a volume of about 13,500 cubic micrometers. The amino amide anesthetic is crystalline and includes 50-70% crystalline form I and 30-50% crystalline form II.
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.
B29C 33/60 - Agents de démoulage, de lubrification ou de séparation
B29C 33/38 - Moules ou noyauxLeurs détails ou accessoires caractérisés par la matière ou le procédé de fabrication
B29C 33/40 - Matière plastique, p. ex. mousse ou caoutchouc
B32B 3/30 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche continue dont le périmètre de la section droite a une allure particulièreProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche comportant des cavités ou des vides internes caractérisés par une couche comportant des retraits ou des saillies, p. ex. des gorges, des nervures
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
G03F 7/00 - Production par voie photomécanique, p. ex. photolithographique, de surfaces texturées, p. ex. surfaces impriméesMatériaux à cet effet, p. ex. comportant des photoréservesAppareillages spécialement adaptés à cet effet
B29C 43/36 - Moules pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés
B32B 37/18 - Procédés ou dispositifs pour la stratification, p. ex. par polymérisation ou par liaison à l'aide d'ultrasons caractérisés par les propriétés des couches toutes les couches existant et présentant une cohésion avant la stratification impliquant uniquement l'assemblage de feuilles ou de panneaux individualisés
B32B 38/00 - Opérations auxiliaires liées aux procédés de stratification
B29C 33/42 - Moules ou noyauxLeurs détails ou accessoires caractérisés par la forme de la surface de moulage, p. ex. par des nervures ou des rainures
B29C 43/22 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur indéfinie
B29C 43/28 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur indéfinie en incorporant des parties ou des couches préformées, p. ex. moulage par pressage autour d'inserts ou sur des objets à recouvrir
The present invention concerns drug delivery particles which can prevent interaction between a biologically-active cargo comprised within the particles and components of an aqueous environment in which said particles are present. The particles are sensitive to p H such that above a threshold p H level the biologically-active cargo becomes accessible to the surrounding environment. Such particles are accordingly useful for stably storing a biologically-active cargo in an aqueous composition containing components which would otherwise interact deleteriously with the cargo, and releasing the cargo to mediate a biological effect in the body of an animal, such as a human, to which the composition is administered. Also provided are compositions comprising such particles, as well as methods for making and using such particles and compositions.
Disclosed are inhalable antiviral pharmaceutical compositions of ribavirin, methods of producing the same, and the use of such compositions in the treatment of virally associated respiratory infections, and associated diseases and conditions.
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
Produits et services
Custom manufacture of micro- and nano-particles, namely, those composed predominantly of polymers, for general scientific and research purposes and used in the manufacture of industrial goods; custom manufacture of micro- and nano- particles, namely, those composed predominantly of polymers or therapeutic or prophylactic or diagnostic agents used for medical purposes
34.
Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.
B29C 33/60 - Agents de démoulage, de lubrification ou de séparation
B29C 33/38 - Moules ou noyauxLeurs détails ou accessoires caractérisés par la matière ou le procédé de fabrication
B29C 33/40 - Matière plastique, p. ex. mousse ou caoutchouc
B32B 3/30 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche continue dont le périmètre de la section droite a une allure particulièreProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche comportant des cavités ou des vides internes caractérisés par une couche comportant des retraits ou des saillies, p. ex. des gorges, des nervures
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
G03F 7/00 - Production par voie photomécanique, p. ex. photolithographique, de surfaces texturées, p. ex. surfaces impriméesMatériaux à cet effet, p. ex. comportant des photoréservesAppareillages spécialement adaptés à cet effet
B29C 43/36 - Moules pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés
B32B 37/18 - Procédés ou dispositifs pour la stratification, p. ex. par polymérisation ou par liaison à l'aide d'ultrasons caractérisés par les propriétés des couches toutes les couches existant et présentant une cohésion avant la stratification impliquant uniquement l'assemblage de feuilles ou de panneaux individualisés
B32B 38/00 - Opérations auxiliaires liées aux procédés de stratification
B29C 33/42 - Moules ou noyauxLeurs détails ou accessoires caractérisés par la forme de la surface de moulage, p. ex. par des nervures ou des rainures
B29C 43/22 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur indéfinie
B29C 43/28 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur indéfinie en incorporant des parties ou des couches préformées, p. ex. moulage par pressage autour d'inserts ou sur des objets à recouvrir
A large area patterned film includes a first patterned area; a second patterned area; and a seam joining the first patterned area and the second patterned area, wherein the seam has a width less than about 20 micrometers. A method for tiling patterned areas includes depositing a predetermined thickness of a curable material; contacting a first portion of the curable material with a mold; curing the first portion of the curable material; removing the mold from the cured first portion of the curable material; contacting a second portion of the curable material with the mold, such that the mold contacts a portion of the cured first portion of the curable material; curing the second portion of the curable material; and removing the mold to yield a seam between the cured first portion of the curable material and the cured second portion of the curable material, wherein the seam has a dimension less than about 20 micrometers.
B29C 59/02 - Façonnage de surface, p. ex. gaufrageAppareils à cet effet par des moyens mécaniques, p. ex. par pressage
B29C 35/08 - Chauffage ou durcissement, p. ex. réticulation ou vulcanisation utilisant l'énergie ondulatoire ou un rayonnement corpusculaire
B29C 43/00 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet
B29C 43/02 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
G03F 7/00 - Production par voie photomécanique, p. ex. photolithographique, de surfaces texturées, p. ex. surfaces impriméesMatériaux à cet effet, p. ex. comportant des photoréservesAppareillages spécialement adaptés à cet effet
B29C 43/14 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés en plusieurs étapes
B29C 35/02 - Chauffage ou durcissement, p. ex. réticulation ou vulcanisation
B29C 37/00 - Éléments constitutifs, détails, accessoires ou opérations auxiliaires non couverts par le groupe ou
B29C 43/06 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés en utilisant des moules mobiles se déplaçant en continu
B29K 105/00 - Présentation, forme ou état de la matière moulée
G02F 1/1333 - Dispositions relatives à la structure
B29K 67/00 - Utilisation de polyesters comme matière de moulage
The disclosure relates to the field of pharmaceutical compositions, implants formed from pharmaceutical compositions, and methods of forming implants. More particularly, the present invention relates to delivering sustained release or depot delivery of radio-protector implants and methods for protecting tissues and glands from side effects of radiation treatment.
A medical device includes a textured surface having a predetermined nanostructure, wherein the nanostructure is less than about 500 nanometers in a broadest dimension. The textures nanostructure surface reduces friction between the medical device and biological tissue.
A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents
A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
Virtual conjugate particles containing an active agent such as an antigenic polysaccharide or a nucleic acid with a charged biomolecule such as a protamine protein are described. The virtual conjugate particles typically contain a polymeric core particle that provides a surface for the association of the agent with a charged biomolecule. A cross-linker may be used to associate the agents with the core particle.
A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.
B29C 33/60 - Agents de démoulage, de lubrification ou de séparation
B32B 38/00 - Opérations auxiliaires liées aux procédés de stratification
B29C 33/40 - Matière plastique, p. ex. mousse ou caoutchouc
B32B 3/30 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche continue dont le périmètre de la section droite a une allure particulièreProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche comportant des cavités ou des vides internes caractérisés par une couche comportant des retraits ou des saillies, p. ex. des gorges, des nervures
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
G03F 7/00 - Production par voie photomécanique, p. ex. photolithographique, de surfaces texturées, p. ex. surfaces impriméesMatériaux à cet effet, p. ex. comportant des photoréservesAppareillages spécialement adaptés à cet effet
B29C 43/36 - Moules pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés
B29C 33/38 - Moules ou noyauxLeurs détails ou accessoires caractérisés par la matière ou le procédé de fabrication
B32B 37/18 - Procédés ou dispositifs pour la stratification, p. ex. par polymérisation ou par liaison à l'aide d'ultrasons caractérisés par les propriétés des couches toutes les couches existant et présentant une cohésion avant la stratification impliquant uniquement l'assemblage de feuilles ou de panneaux individualisés
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
LIQUIDIA TECHNOLOGIES, INC. (USA)
Inventeur(s)
Desimone, Joseph
Hunter, Michael
Moga, Katherine Anne
Abrégé
The present invention provides a system for fabricating a microneedle device and microneedle devices. The system includes depositing a first material on a delivery sheet, introducing the delivery sheet with deposited first material to a mold, passing the delivery sheet with deposited first material and mold through a nip-point to introduce at least a portion of first material into cavities in the mold, and separating the mold from the first material to provide a microneedle device with needles mimicking the cavities of the mold.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.
B29C 33/60 - Agents de démoulage, de lubrification ou de séparation
B29C 33/38 - Moules ou noyauxLeurs détails ou accessoires caractérisés par la matière ou le procédé de fabrication
B29C 33/40 - Matière plastique, p. ex. mousse ou caoutchouc
B32B 3/30 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche continue dont le périmètre de la section droite a une allure particulièreProduits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche comportant des cavités ou des vides internes caractérisés par une couche comportant des retraits ou des saillies, p. ex. des gorges, des nervures
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
G03F 7/00 - Production par voie photomécanique, p. ex. photolithographique, de surfaces texturées, p. ex. surfaces impriméesMatériaux à cet effet, p. ex. comportant des photoréservesAppareillages spécialement adaptés à cet effet
B29C 43/36 - Moules pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés
A system including a mold having a fluoropolymer wherein the mold defines a plurality of cavities having a predetermined shape and a cross-sectional dimension less than about 100 micrometers; a roller; a surface in cooperation with the roller to form a nip point configured to receive the mold, wherein the nip point is further configured to receive a substantially liquid composition and accelerate entry of the substantially liquid composition into the cavity. A method of forming particles including applying a substantially liquid composition to a mold, wherein the mold comprises a fluoropolymer and defines a plurality of cavities each having a broadest cross-sectional dimension of less than about 100 micrometers; nipping the mold between a roller and a surface such that the substantially liquid composition enters the cavities of the mold; and hardening the substantially liquid composition in the cavities of the mold to form a particle within each cavity, wherein the particle has a size and shape that substantially mimics the size and shape of the cavity of the mold.
A large area patterned film includes a first patterned area; a second patterned area; and a seam joining the first patterned area and the second patterned area, wherein the seam has a width less than about 20 micrometers. A method for tiling patterned areas includes depositing a predetermined thickness of a curable material; contacting a first portion of the curable material with a mold; curing the first portion of the curable material; removing the mold from the cured first portion of the curable material; contacting a second portion of the curable material with the mold, such that the mold contacts a portion of the cured first portion of the curable material; curing the second portion of the curable material; and removing the mold to yield a seam between the cured first portion of the curable material and the cured second portion of the curable material, wherein the seam has a dimension less than about 20 micrometers.
B29C 59/02 - Façonnage de surface, p. ex. gaufrageAppareils à cet effet par des moyens mécaniques, p. ex. par pressage
B29C 35/08 - Chauffage ou durcissement, p. ex. réticulation ou vulcanisation utilisant l'énergie ondulatoire ou un rayonnement corpusculaire
B29C 43/00 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet
B29C 43/02 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p. ex. calcul quantique ou logique à un électron
B82Y 40/00 - Fabrication ou traitement des nanostructures
G03F 7/00 - Production par voie photomécanique, p. ex. photolithographique, de surfaces texturées, p. ex. surfaces impriméesMatériaux à cet effet, p. ex. comportant des photoréservesAppareillages spécialement adaptés à cet effet
B32B 27/00 - Produits stratifiés composés essentiellement de résine synthétique
B29C 35/02 - Chauffage ou durcissement, p. ex. réticulation ou vulcanisation
B29C 37/00 - Éléments constitutifs, détails, accessoires ou opérations auxiliaires non couverts par le groupe ou
B29C 43/06 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés en utilisant des moules mobiles se déplaçant en continu
B29C 43/14 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés en plusieurs étapes
B29K 105/00 - Présentation, forme ou état de la matière moulée
G02F 1/1333 - Dispositions relatives à la structure
44.
Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.
B29C 43/06 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés en utilisant des moules mobiles se déplaçant en continu
45.
GEOMETRICALLY ENGINEERED PARTICLES AND METHODS FOR MODULATING MACROPHAGE OR IMMUNE RESPONSES
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
LIQUIDIA TECHNOLOGIES INC. (USA)
Inventeur(s)
Desimone, Joseph
Napier, Mary, Elizabeth
Luft, Chris
Mack, Pete
Maynor, Ben
Shen, Tammy
Abrégé
Disclosed herein are geometrically engineered particles having varied shapes and sizes and surface charge which can incorporate drugs and/or other biomaterials for targeted delivery, such as pulmonary delivery. The size, shape, etc. of a particle can be designed and corresponding particles can be prepared that target or de-target immunological responses to the particles themselves, for example, the response of alveolar macrophages. Methods of modulating immune responses by utilizing the particles are also disclosed. The particles can be composed substantially of therapeutic, drug and polymer or can comprise polymers and proteins. The particles may also be composed of diagnostic agents and additional biomaterials to confer aerosolization and cellular uptake properties. The particles also may have a range of physical features such as fenestrations, angled arms, asymmetry and surface roughness, charge which alter the interactions with cells and tissues.
A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.
B29C 43/06 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés en utilisant des moules mobiles se déplaçant en continu
47.
System and method for producing particles and patterned films
A system including a mold having a fluoropolymer wherein the mold defines a plurality of cavities having a predetermined shape and a cross-sectional dimension less than about 100 micrometers; a roller; a surface in cooperation with the roller to form a nip point configured to receive the mold, wherein the nip point is further configured to receive a substantially liquid composition and accelerate entry of the substantially liquid composition into the cavity. A method of forming particles including applying a substantially liquid composition to a mold, wherein the mold comprises a fluoropolymer and defines a plurality of cavities each having a broadest cross-sectional dimension of less than about 100 micrometers; nipping the mold between a roller and a surface such that the substantially liquid composition enters the cavities of the mold; and hardening the substantially liquid composition in the cavities of the mold to form a particle within each cavity, wherein the particle has a size and shape that substantially mimics the size and shape of the cavity of the mold.
The University of North Carolina at Chapel Hill (USA)
Liquidia Technologies, Inc. (USA)
Inventeur(s)
Desimone, Joseph
Parrott, Matthew
Murphy, Andrew
Petros, Robby A.
Abrégé
The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile —Si-A-C— groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C═O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
LIQUIDIA TECHNOLOGIES, INC. (USA)
Inventeur(s)
Desimone, Joseph, M.
Rolland, Jason, P.
Abrégé
Particles that may be used for the fabrication of micro- and nanoarrays are provided. The particles may comprise one or more target molecules to be delivered to cavities on a substrate. Methods for preparing the particles and for introducing target molecules to the cavities using these particles to produce a micro- or nanoarray are also presented. Additionally, methods of using these micro- or nanoarrays are provided.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
51.
NANOWIRE GRID POLARIZERS AND METHODS FOR FABRICATING THE SAME
A polarizer including a substrate sheet configured with grid elements on at least a first surface, wherein the grid elements have a height to width aspect ratio of at least 1.5: 1, and metal coupled with the grid elements, wherein the metal comprises a height to width aspect ratio greater than the aspect ratio of the grid elements of the substrate.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
LIQUIDIA TECHNOLOGIES, INC. (USA)
Inventeur(s)
Desimone, Joseph, M.
Maynor, Benjamin
Napier, Mary
Pillai, Jonathan
Desimone, Philip
Patrick, Will
Laaker, Kyle
Zhang, Hanjun
Abrégé
An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated nanoparticle body member being non- spherical. The fabricated nanoparticle body member is configured to provide at least one of auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time of the fabricated nanoparticle body member. An associated method is also provided.
B01J 2/22 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par pressage dans des moules ou entre des cylindres
53.
INTERVENTIONAL DRUG DELIVERY SYSTEM AND ASSOCIATED METHODS
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
LIQUIDIA TECHNOLOGIES, INC. (USA)
Inventeur(s)
Desimone, Joseph
Napier, Mary
Pillai, Jonathan
Byrne, James
Roush, Lukas, Miller
Yeh, Jen, Jen
Parrott, Matt
Abrégé
A delivery system for local drug delivery to a target site of internal body tissue is provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A reservoir is configured to be disposed such that the reservoir is capable of interacting with the localized electric field. The reservoir is configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field. Associated methods are also provided.
A large area patterned film includes a first patterned area; a second patterned area; and a seam joining the first patterned area and the second patterned area, wherein the seam has a width less than about 20 micrometers. A method for tiling patterned areas includes depositing a predetermined thickness of a curable material; contacting a first portion of the curable material with a mold; curing the first portion of the curable material; removing the mold from the cured first portion of the curable material; contacting a second portion of the curable material with the mold, such that the mold contacts a portion of the cured first portion of the curable material; curing the second portion of the curable material; and removing the mold to yield a seam between the cured first portion of the curable material and the cured second portion of the curable material, wherein the seam has a dimension less than about 20 micrometers.
B27N 3/18 - Opérations auxiliaires, p. ex. préchauffage, humidification, coupe
B29C 59/02 - Façonnage de surface, p. ex. gaufrageAppareils à cet effet par des moyens mécaniques, p. ex. par pressage
B29C 35/08 - Chauffage ou durcissement, p. ex. réticulation ou vulcanisation utilisant l'énergie ondulatoire ou un rayonnement corpusculaire
B32B 27/00 - Produits stratifiés composés essentiellement de résine synthétique
B32B 3/00 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme
B29C 65/00 - Assemblage d'éléments préformésAppareils à cet effet
A large area patterned film includes a first patterned area; a second patterned area; and a seam joining the first patterned area and the second patterned area, wherein the seam has a width less than about 20 micrometers. A method for tiling patterned areas includes depositing a predetermined thickness of a curable material; contacting a first portion of the curable material with a mold; curing the first portion of the curable material; removing the mold from the cured first portion of the curable material; contacting a second portion of the curable material with the mold, such that the mold contacts a portion of the cured first portion of the curable material; curing the second portion of the curable material; and removing the mold to yield a seam between the cured first portion of the curable material and the cured second portion of the curable material, wherein the seam has a dimension less than about 20 micrometers.
H01L 21/70 - Fabrication ou traitement de dispositifs consistant en une pluralité de composants à l'état solide ou de circuits intégrés formés dans ou sur un substrat commun, ou de parties constitutives spécifiques de ceux-ciFabrication de dispositifs à circuit intégré ou de parties constitutives spécifiques de ceux-ci
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
LIQUIDIA TECHNOLOGIES, INC. (USA)
Inventeur(s)
Zhou, Zhilian
Meng, Xiansheng, Sean
Desimone, Joseph
Maynor, Benjamin
Rolland, Jason
Wiles, Kenton, B.
Abrégé
A membrane is provided, comprising a first membrane layer having a first side and a second side. The first membrane layer defines a plurality of holes extending along a first axis between the first side and the second side. Each hole is defined by the first membrane layer as a complex three-dimensional shape, and each hole has a diameter of less than about 10 micrometers. The membrane is fabricated by dispersing a liquid polymeric material onto a patterned master template, hardening the polymeric material, and removing it from the master template. The membrane includes through holes which correspond to the structures of the patterned master template in size, cross-sectional and three dimensional shape, orientation, and the like.
A nanoparticle is fabricated from a reaction of a polymer, a crosslinker, a nucleic acid, and between about 2 wt% and about 75 wt% of a charged monomer within a cavity of a mold resulting in a particle having a substantially predetermined three dimensional shape and a largest cross-sectional dimension of less than about 5 micron. The mold can include perfluoropoly ether and the nucleic acid can include less than about 30 nucleotides and the polymer can be poly( vinyl pyrrolidinone). The particles can be washed after being molded and the mold can include less than about 1 wt% initiator, less than about 0.5 wt% initiator, or less than about 0.1 wt% initiator.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
LIQUIDIA TECHNOLOGIES, INC. (USA)
Inventeur(s)
Desimone, Joseph
Parrott, Matthew
Murphy, Andrew
Petros, Robby, A.
Abrégé
The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile -Si-A-C- groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C=O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
C07F 7/08 - Composés comportant une ou plusieurs liaisons C—Si
B82B 1/00 - Nanostructures formées par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
59.
Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
A medical device includes a textured surface having a predetermined nanostructure, wherein the nanostructure is less than about 500 nanometers in a broadest dimension. The textures nanostructure surface reduces friction between the medical device and biological tissue.
A method of stimulating an immune response in a subject including administering a micrometer-sized particle coupled with an antigen to the subject, wherein increasing the aspect ratio of the micrometer-sized particle increases the immune response. A method of stimulating an immune response in a subject including administering to the subject a plurality of particles, wherein each particle is coupled with an immuno stimulating agent and a protein. A vaccine particle composition including a plurality of particles configured to release a first protein at a first rate and a second protein at a second rate and configured to provide priming and boosting capability in a single dose.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
LIQUIDIA TECHNOLOGIES, INC. (USA)
Inventeur(s)
Desimone, Joseph, M.
Roush, Lukas, Miller
Enlow, Elizabeth, Marti
Napier, Mary, Elizabeth
Abrégé
A delivery apparatus for delivering a cargo to a target site of internal body tissue is provided. The delivery apparatus comprises a flexible tubular member having a distal end adapted for insertion proximate to the target site. A first electrode is configured for insertion within the flexible tubular member such that the first electrode is capable of being disposed proximate to the target site. A second electrode is configured to cooperate with the first electrode to form an electric field. A delivery component has a cargo carried thereby and is coupled with the first electrode. The delivery component is configured to degrade when exposed to the electric field such that the cargo is released to the target site upon degradation thereof. An associated method is also provided.
A system including a mold having a fluoropolymer wherein the mold defines a plurality of cavities having a predetermined shape and a cross-sectional dimension less than about 100 micrometers; a roller; a surface in cooperation with the roller to form a nip point configured to receive the mold, wherein the nip point is further configured to receive a substantially liquid composition and accelerate entry of the substantially liquid composition into the cavity. A method of forming particles including applying a substantially liquid composition to a mold, wherein the mold comprises a fluoropolymer and defines a plurality of cavities each having a broadest cross-sectional dimension of less than about 100 micrometers; nipping the mold between a roller and a surface such that the substantially liquid composition enters the cavities of the mold; and hardening the substantially liquid composition in the cavities of the mold to form a particle within each cavity, wherein the particle has a size and shape that substantially mimics the size and shape of the cavity of the mold.
B28B 5/00 - Fabrication d'objets façonnés à partir du matériau dans des moules ou sur des surfaces de moulage, supportés ou constitués par des transporteurs à l'intérieur ou sur ceux-ci, quel que soit le mode de façonnage
B28B 3/12 - Fabrication d'objets façonnés en utilisant des pressesPresses spécialement adaptées à ce travail dans laquelle un ou plusieurs cylindres exercent une pression sur le matériau
63.
SYSTEM AND METHOD FOR PRODUCING PARTICLES AND PATTERNED FILMS
A mold having a fluoropolymer wherein the mold defines cavities having a shape and a cross-sectional dimension less than 100 micrometers, a roller, a surface in cooperation with the roller to form a nip point to receive the mold, wherein the nip point receives a liquid and accelerates entry of the liquid into the cavity Forming particles includes applying a liquid to a mold, wherein the mold comprises a fluoropolymer and defines a cavities each having a broadest crosssectional dimension of less than 100 micrometers, nipping the mold between a roller and a surface such that the liquid enters the cavities of the mold, and hardening the liquid in the cavities of the mold to form a particle within each cavity, wherein the particle has a size and shape that mimics the size and shape of th cavity of the mold
B32B 5/16 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par le fait qu'une des couches est formée de particules, p. ex. de copeaux, de fibres hachées, de poudre
B28B 3/00 - Fabrication d'objets façonnés en utilisant des pressesPresses spécialement adaptées à ce travail
64.
METHODS AND MATERIALS FOR FABRICATING LAMINATE NANOMOLDS AND NANOPARTICLES THEREFROM
A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.
B05D 3/12 - Traitement préalable des surfaces sur lesquelles des liquides ou d'autres matériaux fluides doivent être appliquésTraitement ultérieur des revêtements appliqués, p. ex. traitement intermédiaire d'un revêtement déjà appliqué, pour préparer les applications ultérieures de liquides ou d'autres matériaux fluides par des moyens mécaniques
B32B 1/00 - Produits stratifiés ayant une forme non plane
65.
NANOARRAYS AND METHODS AND MATERIALS FOR FABRICATING SAME
A nanoarray includes a fluoropolymer array defining a plurality of cavities where each cavity has a predetermined shape and is less than about 5 micrometers in a broadest cross-sectional dimension. The nanoarray also includes a composition discretely contained in each cavity, where the composition includes a linking group for coupling with a modifying group. The nanoarray can be fabricated from fluoropolyether or perfluoropolyether.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
LIQUIDIA TECHNOLOGIES INC. (USA)
Inventeur(s)
Desimone, Joseph, M.
Henn, Robert, Lyon
Nunes, Janine
Du, Libin
Abrégé
A polymer composite includes a polymer and an additive encased in the polymer, wherein the additive includes a plurality of isolated particles where each particle of the plurality of particles has a substantially predetermined three dimensional shape and is substantially oriented with respect to each other in a predetermined two dimensional array.
A laminate nanomold includes a layer of perfluoropolyether defining a cavity that has a predetermined shape and a support layer coupled with the layer of perfluoropolyether. The laminate can also include a tie-layer coupling the layer of perfluoropolyether with the support layer. The tie-layer can also include a photocurable component and a thermal curable component. The cavity can have a broadest dimension of less than 500 nanometers.
B29C 43/06 - Moulage par pressage, c.-à-d. en appliquant une pression externe pour faire couler la matière à moulerAppareils à cet effet pour la fabrication d'objets de longueur définie, c.-à-d. d'objets séparés en utilisant des moules mobiles se déplaçant en continu
68.
NANOPARTICLES HAVING FUNCTIONAL ADDITIVES FOR SELF AND DIRECTED ASSEMBLY AND METHODS OF FABRICATING SAME
A plurality of nanoparticles, a structure assembled therefrom, a method of forming the structure, including a plurality of particles where each particle of the plurality of particles is configured with a substantially predetermined shape and a largest dimension less than about 100 micrometers, and where each particle of the plurality of particles includes an opening through the particle.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
Produits et services
Micro- and nano-particles, namely, those composed of polymers, used for general scientific and research purposes; micro- and nano-particles, namely, those composed predominantly of polymers, used in the manufacture of industrial goods; micro- and nano-particles, namely, those composed predominantly of polymers modified with an encapsulated or surface-coated substance that provides identification, used in industrial goods Micro- and nano-particles, namely, those composed of polymers, therapeutics or excipients used for medical diagnostic and treatment purposes Custom manufacture of micro- and nano-particles, namely, those composed predominantly of polymers, for general scientific and research purposes and used in the manufacture of industrial goods; custom manufacture of micro- and nano-particles, namely, those composed predominantly of polymers or therapeutics used for medical purposes
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Micro- and nano-particles, namely, those composed predominantly of polymers, therapeutics or excipients used for medical diagnostic and treatment purposes
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
Produits et services
[ Micro- and nano-particles, namely, those composed of polymers, used for general scientific and research purposes; micro- and nano-particles, namely, those composed predominantly of polymers, used in the manufacture of industrial goods other than those used for printing purposes ] Custom manufacture of micro- and nano-particles, namely, those composed predominantly of polymers, for general scientific and research purposes and used in the manufacture of industrial goods other than those used for printing purposes; custom manufacture of mico- and nano-particles, namely, those composed predominantly of polymers or therapeutics used for medical purposes
